Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide

F. Santos, M. J. Smith and J. C. Chan

Urine calcium excretion was evaluated in 19 patients before and after calcitriol (1,25-dihydroxyvitamin D3) treatment that was followed up for a five- to seven-year period. The effects of increases of calcitriol dosage and modifications of calciuria with hydrochlorothiazide were systematically examined. The urine calcium excretion before calcitriol therapy was 2.3 +/- 0.8 mg/kg/day (mean- +/- SEM) and the urine calcium-creatinine concentration ratio was 0.12 +/- 0.04. With the dose of calcitriol at 23 ng/kg/day, these values increased to 3.2 +/- 0.8 mg/kg/day and 0.19 +/- 0.04, respectively. Following double dose of calcitriol (44 ng/kg/day), increments in calciuria and urinary calcium/creatinine concentration of 1.4 +/- 0.6 mg/kg/day and 0.10 +/- 0.03, respectively, were observed. With concomitant administration of hydrochlorothiazide (1 to 2 mg/kg/day) therapy at maintenance dose and calcitriol (31 ng/kg/day), the urine calcium excretion effectively decreased by 1.3 +/- 0.6 mg/kg/day and the urine calcium-creatinine concentration ratio by 0.05 +/- 0.02. The results suggest that children with calcium-phosphate disorders who require long-term treatment with calcitriol must be carefully monitored in terms of urine calcium excretion, especially when the dosages are increased to achieve maximal therapeutic efficacy. Calciuria induced by calcitriol administration is effectively reversed by addition of hydrochlorothiazide to the treatment regimen.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients
Riechelmann et al.
JNCI J Natl Cancer Inst 2007;99:592-600.
ABSTRACT | FULL TEXT  

Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1-34) Versus Calcitriol and Calcium
Winer et al.
J. Clin. Endocrinol. Metab. 2003;88:4214-4220.
ABSTRACT | FULL TEXT  

Hydrochlorothiazide Effectively Reduces Urinary Calcium Excretion in Two Japanese Patients with Gain-of-Function Mutations of the Calcium-Sensing Receptor Gene
Sato et al.
J. Clin. Endocrinol. Metab. 2002;87:3068-3073.
ABSTRACT | FULL TEXT  

Thiazide Diuretics Arrest the Progression of Nephrocalcinosis in Children With X-Linked Hypophosphatemia
Seikaly and Baum
Pediatrics 2001;108:e6-6.
ABSTRACT | FULL TEXT  

A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1-34 in Treatment of Hypoparathyroidism
Winer et al.
J. Clin. Endocrinol. Metab. 1998;83:3480-3486.
ABSTRACT | FULL TEXT  

Familial Hypoparathyroidism: Identification of a Novel Gain of Function Mutation in Transmembrane Domain 5 of the Calcium-Sensing Receptor
Watanabe et al.
J. Clin. Endocrinol. Metab. 1998;83:2497-2502.
ABSTRACT | FULL TEXT  

Sporadic Hypoparathyroidism Caused by de Novo Gain- of-Function Mutations of the Ca2+-Sensing Receptor
De Luca et al.
J. Clin. Endocrinol. Metab. 1997;82:2710-2715.
ABSTRACT | FULL TEXT